MFMark Aaron Fiala

Mark Aaron Fiala

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mark Aaron Fiala has a total of 588 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • The Association of Allostatic Load with MGUS Incidence and Risk for Progression to Multiple Myeloma

    by Mark A. Fiala, Qingyuan Tan, Mei Wang, Han Zhao, Matin W. Schoen, Kristen M. Sanfilippo, Theordore S. Thomas, Michael J. Slade, Ravi Vij, Su-Hsin Chang

  • The association between allostatic load and monoclonal gammopathy of undetermined significance ( MGUS )

    by Mark A. Fiala, Tuo Lan, Michael J. Slade, Ravi Vij, Su‐Hsin Chang


  • Open Access

    Impact of Financial Incentives on Electronic Health Record–Driven Recruitment of Underrepresented Communities in Research: Randomized Controlled Trial

    by Christina Ping, Andrew A Davis, Waishun Gema, Foluso Ademuyiwa, Mark Fiala

    Background: Progress in clinical trial research depends on effective recruitment to ensure adequate sample sizes and generalizability of results. Electronic health record (EHR)–based recruitment has been suggested as a potential method to address historical imbalances in trial populations, including underrepresentation of certain racial and ethnic groups. However, disparities in EHR portal uptake and use exist, particularly among these same underrepresented groups. Thus, we hypothesized that EHR-driven recruitment for research may continue to exacerbate these dynamics. Objective: In this study, we evaluated whether a financial incentive improved response rates to recruitment messages delivered through an EHR portal in an equitable fashion. Methods: A random sample of 1200 patients with diagnoses of breast, colorectal, prostate, or lung cancer and active EHR patient portal accounts received an automated recruitment message for a fictitious cross-sectional survey study, “The Social Aspects of Cancer Care,” via their EHR portal. Two strata of patients were sampled, those who identified as non-Hispanic White individuals (n=600, 50%) and those who identified as part of a historically underrepresented racial or ethnic group (n=600, 50%), and randomized to receive an offer of a US $20 monetary incentive (n=400, 33.3%) or no incentive (n=800, 66.7%). Patients were given 14 days to respond. Results: Overall, 39.3% (471/1200) of participants viewed the recruitment message, and 13.3% (159/1200) responded that they were interested. Response rates were higher ( P <.001) among non-Hispanic White patients (108/600, 18%) than among African American or Black patients (32/456, 7%) and members of other racial or ethnic groups (18/144, 12.5%). Older patients (≥65 years) were less likely to view the recruitment message (244/720, 33.9% vs 230/480, 47.9%; P =.001) and respond (72/720, 10% vs 82/480, 17.1%; P =.002). Sex was not significantly associated with viewing the message or response outcomes ( P =.45 and P =.19, respectively). No differences were observed in response rate for the incentive cohort compared to the cohort with no incentive (60/400, 15% vs 96/800, 12%; P =.21). Conclusions: Patients with cancer who identify as part of a historically underrepresented group were less likely to view and respond to recruitment messages for research studies through their EHR patient portal. Age was also found to significantly impact engagement, with older patients less likely to view and respond. Finally, a modest US $20 financial incentive was not found to significantly impact patient engagement.

  • Neuroimaging Biomarkers of Disease Progression and Cognitive Change in Patients With Retinal Vasculopathy With Cerebral Leukoencephalopathy

    by Andria L. Ford, Peter Kang, Slim Fellah, Serguei V. Astafiev, April Ratliff, Mark Fiala, Yan Wang, Vivian Chen, Sydney Panagos, Henok Getahun, et al.

    A monogenic, age-related cerebral small vessel disease (cSVD), retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestations (RVCL-S), causes accelerated vascular dementia, vision loss, and premature death. Given knowledge is limited regarding its pathophysiology, we examined the natural history of progression in imaging and cognitive endpoints to define the rate and variability of progression in a prospective RVCL-S cohort. We hypothesized that cerebral blood flow (CBF) and oxygen extraction fraction (OEF), as metrics of cerebral hypoxia-ischemia, would be associated with neurologic disease progression. We performed sequential brain MRI and a cognitive battery in a prospective RVCL-S cohort. Arterial spin labeling and asymmetric spin echo quantified CBF and OEF in normal-appearing white matter (WM), respectively. Three neuroimaging endpoints of cSVD included the following: log-transformed, normalized fluid-attenuated inversion recovery WM hyperintensity (WMH) volume; WM microstructure using mean diffusivity; and normalized WM volume. Five cognitive and motor endpoints included Digit Symbol Substitution Test (DSST), category fluency, free recall, Montreal Cognitive Assessment (MoCA), and gait speed. Linear mixed-effects models examined age, CBF, and OEF in association with neuroimaging and cognitive progression. Twenty-five participants, aged 23-68 years (median 47 years, 56% female), underwent 151 scans over a median (25th, 75th) of 2.2 (1.8, 4.4) years. All neuroimaging and cognitive endpoints progressed over time, except for MoCA. Of neuroimaging endpoints, WMH volume demonstrated the largest rate of change (+31.3%/year, 95% CI 20.8%-42.3%). Of cognitive endpoints, DSST, a metric of processing speed, showed the steepest decline (-13.1 T-score points/decade, 95% CI -21.2 to -5.32), followed by free recall and category fluency (-5 [-7.9 to -2.4] and -4.1 [-7.2 to -1.2] T-score points per decade, respectively). The age at first brain lesion was estimated to be 30.6 (23.8, 35.8) years, modeled from individual WMH volume trajectories. In multivariable analysis, OEF, but not CBF, was independently associated with WMH growth (β = 3.73, 95% CI 0.63-6.83, p = 0.029) and change in WM microstructure (β = 0.175, 95% CI 0.029-0.32, p = 0.029). Neither OEF nor CBF was independently associated with cognitive decline. Elevated OEF in at-risk WM was associated with progression in WMH and impairment in WM microstructure, suggesting a role for tissue hypoxia-ischemia in underlying RVCL-S pathophysiology. Cerebral OEF holds promise as a predictive biomarker to risk-stratify patients with RVCL-S and other forms of cSVD.


  • Top Cited Papers
    Open Access

    A single-cell atlas characterizes dysregulation of the bone marrow immune microenvironment associated with outcomes in multiple myeloma

    by William C. Pilcher, Lijun Yao, Edgar Gonzalez-Kozlova, Yered Pita-Juarez, Dimitra Karagkouni, Chaitanya R. Acharya, Marina E. Michaud, Mark Hamilton, Shivani Nanda, Yizhe Song, et al.

    Multiple myeloma (MM) remains incurable despite advances in treatment options. Although tumor subtypes and specific DNA abnormalities are linked to worse prognosis, the impact of immune dysfunction on disease emergence and/or treatment sensitivity remains unclear. We developed an Immune Atlas of MM by generating profiles of 1,397,272 single cells from the bone marrow (BM) of 337 newly diagnosed participants and characterized immune and hematopoietic cell populations. Cytogenetic risk-based analysis revealed heterogeneous associations with T cells of BM, with 17p13 deletion showing distinct enrichment of a type 1 interferon signature. The disease progression-based analysis revealed the presence of a proinflammatory immune senescence-associated secretory phenotype in rapidly progressing participants. Furthermore, signaling analyses suggested active intercellular communication involving a proliferation-inducing ligand and B cell maturation antigen, potentially promoting tumor growth and survival. Lastly, using independent discovery and validation cohorts, we demonstrated that integrating immune cell signatures with known tumor cytogenetics and individual characteristics significantly improves stratification for the prediction of survival.


  • High-Deductible Health Plans and Out-of-Pocket Health Care Costs Among Younger Patients With Multiple Myeloma

    by Mark Aaron Fiala, Mengmeng Ji, Michael Slade, John H. Huber, Yi-Hsuan Shih, Mei Wang, Graham A. Colditz, Shi-Yi Wang, Ravi Vij, Su-Hsin Chang

    PURPOSE: This study aimed to determine if high-deductible health plan (HDHP) enrollment contributes to financial burden and hinders access to care for patients with multiple myeloma (MM). MATERIALS AND METHODS: Patients diagnosed with MM from 2010 to 2020 were identified in Merative MarketScan, an employer-based health insurance database. Primary outcomes were total health care and out-of-pocket (OOP) costs in the year after diagnosis. Secondary outcomes included time to treatment initiation and stem-cell transplant receipt. Multivariable analyses using linear, logistic, and Cox regression were performed, as appropriate. Covariates included age, sex, year diagnosed, comorbidities, data provider, and stem-cell transplant receipt. RESULTS: The cohort included 4,029 patients; 17.6% were enrolled on HDHPs. HDHP enrollees were younger (mean age, 54.9 v 55.5 years; P = .036). Over the first year, mean total and OOP costs were $406,401 in US dollars (USD) and $9,220 USD for HDHP enrollees, respectively, versus $386,802 USD ( P = .027) and $7,021 USD ( P < .001) for the standard plan enrollees. There was no statistically significant difference in total cost (β = 11; P = .999) but mean OOP costs were $2,544 USD (β = 2,544; P < .001) higher for HDHP enrollees after adjusting for covariates. The additional OOP costs incurred in the first 2 months, presumably because of deductibles, and after the deductible reset. Contrary to our hypothesis, HDHPs enrollees had shorter time to treatment initiation (median, 20 v 22 days; hazard ratio, 1.18; P < .001) and were more likely to receive a stem-cell transplant (55.1% v 47.6%; odds ratio, 1.25; P = .010), after adjusting for covariates. CONCLUSION: Compared with standard plan enrollees, OOP costs were higher for HDHP enrollees in the year after diagnosis, but HDHP enrollment was not associated with delays in treatment initiation or reduced access to stem-cell transplant.

  • Open Access

    Supplementary Figures from Single-Cell Discovery and Multiomic Characterization of Therapeutic Targets in Multiple Myeloma

    by Lijun Yao, Julia T. Wang, Reyka G. Jayasinghe, Julie O'NEal, Chia-Feng Tsai, Michael P. Rettig, Yizhe Song, Ruiyang Liu, Yanyan Zhao, Omar M. Ibrahim, et al.

  • Open Access

    Table S6 from Single-Cell Discovery and Multiomic Characterization of Therapeutic Targets in Multiple Myeloma

    by Lijun Yao, Julia T. Wang, Reyka G. Jayasinghe, Julie O'NEal, Chia-Feng Tsai, Michael P. Rettig, Yizhe Song, Ruiyang Liu, Yanyan Zhao, Omar M. Ibrahim, et al.

    Pearson R correlation values between bulk RNA expression and scRNA expression in PCs for target genes.